Cerdulatinib hydrochloride is primarily used in the research and development of treatments for hematological malignancies and autoimmune disorders. It functions as a dual inhibitor of JAK (Janus kinase) and SYK (spleen tyrosine kinase), two key signaling enzymes involved in immune cell activation and proliferation. This dual inhibition makes it particularly valuable in targeting pathways that drive abnormal immune responses and cancer cell survival. Its application is prominent in studies related to B-cell lymphomas, chronic lymphocytic leukemia (CLL), and other B-cell receptor-driven cancers, where SYK and JAK-STAT signaling pathways play critical roles. Additionally, it has shown potential in preclinical models of inflammatory and autoimmune conditions such as rheumatoid arthritis and lupus, due to its ability to suppress cytokine signaling and immune cell activation. Because of its targeted mechanism, Cerdulatinib hydrochloride is used as a tool compound in pharmacological studies to dissect signaling pathways and evaluate therapeutic efficacy in immune-oncology and inflammation research. It is not currently approved for clinical use but remains an important molecule in the development of novel kinase inhibitors.